Leeds Teaching Hospitals NHS Trust and Novartis Pharmaceuticals UK
Joint working partner(s): Novartis Pharmaceuticals and Leeds Teaching Hospitals NHS Trust
Project Period: Twelve months.
Project name: The Development of the Seacroft wet AMD Service.
Joint working project summary:
Wet age related macular degeneration is a rapidly progressing eye disease which results in loss of central vision and difficulty with performing activities of daily living. Current management requires monthly assessments and regular eye injections.
Seek to demonstrate the benefits to patients of joint working between Leeds Teaching Hospitals NHS Trust and Novartis to improve the quality of ophthalmological care through the development of a new Wet AMD service to be located at Seacroft Hospital. The service will be capable of offering intravitreal assessment and/or treatment for wet Age Related Macular Degeneration (AMD) in order to increase capacity, improve the overall delivery of eye services across Leeds, and optimise clinical outcomes for existing wet AMD patients.
Expected patient outcomes for this project:
Increased patient throughput
Reduction in average follow-up interval
Increase in patient satisfaction resulting from shorter appointment times
Improved patient outcomes
Reduction in the number of Critical Incidence Reports